Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Trace Neu­ro­science, a start­up spun out of Maze Ther­a­peu­tics’ pipeline, broke cov­er Tues­day morn­ing with $101 mil­lion in fund­ing to de­vel­op treat­ments for amy­otroph­ic lat­er­al …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER